一项比较西普利珠单抗与兔抗胸腺细胞球蛋白帮助身体接受肾移植的研究 (MODERNIZE1)
Siplizumab (TCD601) 对比兔抗胸腺细胞球蛋白用于需要诱导治疗且接受他克莫司、霉酚酸和皮质类固醇标准免疫抑制治疗的肾移植受者的 2b 期、随机、多中心、双盲、剂量探索、阳性对照研究
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
研究概览
详细说明
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西、30150-320
- 招聘中
- Santa Casa Demisericordia de Belo Horizonte
-
接触:
- Pedro Macedo de Souza
- 电话号码:+55 (31) 3238-8975
- 邮箱:pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90035-903
- 招聘中
- Hospital de Clinicas de Porto Alegre
-
接触:
- Research Coordinator
- 电话号码:+55 51 3359-6253
- 邮箱:l-genetica@hcpa.edu.br
-
Porto Alegre、Rio Grande do Sul、巴西、90020-090
- 招聘中
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
接触:
- Research Coordinator
- 电话号码:+55 51 3214-8640
- 邮箱:pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto、São Paulo、巴西、15090-000
- 招聘中
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
接触:
- Research Coordinator
- 电话号码:+55 (17) 3201-5054
- 邮箱:osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo、São Paulo、巴西、04038-002
- 招聘中
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
接触:
- Research Coordinator
- 电话号码:+55 (11) 5087-8110
- 邮箱:hospital@hrim.com.br
-
-
-
-
California
-
Los Angeles、California、美国、90033
- 招聘中
- Keck Hospital of the University of Southern California
-
接触:
- Melissa Ramos
- 电话号码:323-442-7983
- 邮箱:Melissa.Ramos@med.usc.edu
-
Los Angeles、California、美国、90095
- 招聘中
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
接触:
- Suphamai Bunnapradist, MD
- 电话号码:310-794-8516
- 邮箱:bunnapradist@mednet.ucla.edu
-
Sacramento、California、美国、95817
- 招聘中
- UC Davis Medical Center
-
接触:
- Timothy Huynh, Clinical Research Coordinator
- 电话号码:916-703-4471
- 邮箱:ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa、Florida、美国、33606
- 招聘中
- Tampa General Hospital
-
接触:
- Jennifer Schmidt, BSN, RN
- 电话号码:813-844-7041
- 邮箱:jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University Hospital
-
接触:
- Emily Temponi, Study Coordinator
- 电话号码:404-712-1114
- 邮箱:emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 招聘中
- University of Kansas Hospital
-
接触:
- Adam Schooley, MA, CCRP
- 电话号码:913-588-1699
- 邮箱:aschooley@kumc.edu
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 招聘中
- University of Kentucky Healthcare
-
接触:
- Malay Shah, MD
- 电话号码:859-338-1615
- 邮箱:malay.shah@uky.edu
-
-
Louisiana
-
Metairie、Louisiana、美国、70006
- 招聘中
- Tulane Medical Center
-
接触:
- Nicole Jackson
- 电话号码:504-988-5344
- 邮箱:njackson3@tulane.edu
-
-
Massachusetts
-
Worcester、Massachusetts、美国、01655
- 招聘中
- UMass Chan Medical Center
-
接触:
- Anil Chandraker, MD
- 电话号码:508-334-7087
- 邮箱:anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan - Michigan Medicine
-
接触:
- Nerissa Reister, Clinical Research Coordinator
- 电话号码:734-763-5718
- 邮箱:naflow@med.umich.edu
-
Detroit、Michigan、美国、48202
- 招聘中
- Henry Ford Health
-
接触:
- Matthew Callaghan
- 电话号码:313-916-4596
- 邮箱:mcallag2@hfhs.org
-
-
New Jersey
-
Livingston、New Jersey、美国、07039
- 招聘中
- Cooperman Barnabus Medical Center
-
接触:
- Jayrol Mock, APN
- 电话号码:973-322-2339
- 邮箱:Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- New York Presbyterian - Columbia University Irving Medical School
-
首席研究员:
- Lloyd Ratner, MD
-
接触:
- Angela Sanchez, CRC
- 电话号码:212-305-3839
- 邮箱:as5546@cumc.columbia.edu
-
接触:
- Theresa Lukose, Research Director
- 电话号码:212-305-3839
- 邮箱:tt2103@cumc.columbia.edu
-
New York、New York、美国、10065
- 招聘中
- New York Presbyterian - Weill Cornell Medical Center
-
接触:
- Jennifer Lee
- 电话号码:212-746-0192
- 邮箱:jel9109@nyp.org
-
接触:
- Meredith Aull
- 电话号码:212-746-5330
- 邮箱:mea9008@med.cornell.edu
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center
-
接触:
- Lynnette Moats
- 电话号码:919-949-6574
- 邮箱:lynnette.moats@duke.edu
-
-
Texas
-
Dallas、Texas、美国、75390
- 招聘中
- University of Texas Southwestern Medical Center
-
接触:
- David Wojciechowski, DO
- 电话号码:214-645-7846
- 邮箱:David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church、Virginia、美国、22042
- 招聘中
- Inova Fairfax Hospital
-
接触:
- Alma Khan, MSN, CCRC
- 电话号码:703-776-5912
- 邮箱:Alma.Khan2@inova.org
-
Richmond、Virginia、美国、23298
- 招聘中
- Virginia Commonwealth University Health
-
接触:
- Meron Zeleke
- 电话号码:804-628-4969
- 邮箱:Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle、Washington、美国、98195
- 招聘中
- University of Washington Medical Center
-
接触:
- Belinda Pan, Research Coordinator
- 电话号码:206-598-1562
- 邮箱:bcpan@uw.edu
-
-
-
-
-
Barcelona、西班牙、08035
- 招聘中
- Hospital Universitari Vall D'Hebron
-
接触:
- Study Coordinator
- 电话号码:+34 932746000
- 邮箱:assajos.nefrologia@vhir.org
-
Córdoba、西班牙、14004
- 招聘中
- Hospital Universitario Reina Sofía
-
接触:
- Álvaro Torres, MD
- 电话号码:+34 957010440
- 邮箱:nefro.hrs.sspa@juntadeandalucia.es
-
Málaga、西班牙、29010
- 招聘中
- Hospital Universitario Regional de Malaga
-
接触:
- Study Coordinator
- 电话号码:+34 951291174
- 邮箱:estudios.clinicos@ibima.eu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:低剂量西普利珠单抗
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
其他名称:
|
|
实验性的:高剂量西普利珠单抗
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
其他名称:
|
|
有源比较器:兔抗胸腺细胞球蛋白
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
大体时间:12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
大体时间:12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
大体时间:12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
大体时间:12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
大体时间:12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
大体时间:12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
大体时间:12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
大体时间:12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
大体时间:12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
大体时间:12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.